NLS Pharma Business

Oxcia has been granted Orphan Drug Designation (ODD) by the FDA for OXC-201, its drug candidate for idiopathic pulmonary fibrosis (IPF), just weeks after a similar decision from the EMA.

Zealand Pharma has signed an exclusive license agreement with newly formed US biopharmaceutical company Elvinix, granting the rights to develop and commercialize a GLP-1/gastrin dual-agonist peptide portfolio as a regenerative therapy for type 1 diabetes.

The US Food and Drug Administration has approved Orexo's Investigational New Drug application for OX640, a needle-free intranasal powder formulation of adrenaline, allowing the company to begin its pivotal clinical development program for the treatment of anaphylaxis.

ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.

The US FDA has granted Orphan Drug Designation to Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for the treatment of endogenous Cushing's syndrome, adding to a growing list of rare-disease designations for the candidate across three regions.

Novo Nordisk has unveiled a rebrand centred on the tagline "Lasting Health Starts Now" and a shortened public-facing name, "Novo," alongside a new set of cultural principles called "The Novo Way" aimed at increasing focus and speed across the organisation.